Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or South Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to South Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. South Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

David Chetrit (NPI 1285155010)

Field	Value
Entity Type	Individual
Organization	David Chetrit
Address	945 82nd Pkwy
City	Myrtle Beach
State	SC
ZIP	29572
Taxonomy	Rheumatology Physician
NPI Enumerated	July 1, 2017

Payer Source	Total Paid
Medicare	$2.3M
Medicaid	$0

Key Findings

This provider’s Medicare practice is heavily focused on physician‑administered biologic infusions: the top revenue drivers are J0129 (28.9K claims, $980.9K revenue, 42.2% of provider Medicare revenue), J1602 (40.4K claims, $444.8K revenue, 19.2%), and J0717 (72K claims, $288K revenue, 12.4%), and the precomputed top 3 codes account for 73.8% of this provider's total Medicare revenue. The presence of multiple infusion and chemotherapy administration codes (96413 $36.5K; 96401 $22K; 96365 $17.7K) further supports an infusion/infusion‑capable office model rather than a primarily office‑visit only practice.

Revenue concentration is material: J0129 alone represents $980.9K or 42.2% of the provider’s Medicare revenue and the top three codes together make up 73.8% of total Medicare receipts. That concentration implies the practice’s financial performance is closely tied to continued billing for these specific biologic infusion products.

This provider is effectively single‑payer in the available data: Total Medicare revenue is $2.3M while Medicaid shows none (no Medicaid billing on file), indicating the entity bills Medicare almost exclusively and has no recorded Medicaid activity to diversify payer risk. Analysts should therefore treat Medicare reimbursement trends and formulary/access changes for infused biologics as the primary revenue risk factors.

Competitive standing on key drugs is elevated for some products and typical for others: J0129 ranks #53 of 1221 providers nationally (96th percentile) and is described as notably above typical national volume for this code, signaling a major national footprint for abatacept infusions. By contrast J1602 (rank #76 of 1041, 93th percentile) and J0717 (rank #249 of 848, 71th percentile) are characterized as typical, unremarkable volumes, suggesting strength concentrated on a subset of biologics rather than uniformly high volume across all agents.

Clinical mix includes significant E/M volume at higher complexity: 99214 has 868 claims, $73.8K revenue and ranks #16174 of 479517 providers (97th percentile) and 99204 (135 claims, $15.4K revenue) ranks in the 94th percentile and is described as notably above typical national volume. This pattern indicates the practice not only administers infusions but also manages moderately complex established patients and a higher‑than‑typical share of new patient visits.

Operationally, code-level descriptors indicate infusions are provided under physician supervision rather than self‑administered drug distribution (the J0129 and J0717 descriptors note use when administered under direct physician supervision). That supports the inference of an on‑site infusion suite or infusion nursing capability as a core service line.

Tenure and credentialing are mature but not long historic: the NPI was enumerated on 2017-07-01 (~9 years ago), so the provider has several years of billing history but is not a decades‑long incumbent. This tenure is sufficient to establish repeat infusion volumes but suggests growth or market penetration could still be ongoing.

Secondary services and diagnostics (lab panels and imaging) appear as adjuncts rather than primary revenue sources—examples include 80053 CMP ($4.3K), 86480 TB interferon ($4.6K), and 76881 joint ultrasound ($5K). These smaller revenue lines are consistent with a rheumatology practice that centers revenue on infused biologics while maintaining in‑office testing and procedural support.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

44 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	28,850	$30	$980.9K
J1602	Injection, golimumab, 1 mg, for intravenous use	40,440	$10	$444.8K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	72,000	$1	$288K
J3262	Injection, tocilizumab, 1 mg	52,720	$10	$263.6K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	3,110	$30	$81K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	870	$90	$73.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	400	$90	$36.5K
J0897	Injection, denosumab, 1 mg	1,440	$20	$27.4K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	430	$50	$22K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	150	$120	$18.3K

Showing 1–10 of 44

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 44 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. South Carolina Distribution

David Chetrit — 0 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — South Carolina

Full comparison — all codes billed, vs. state median

44 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	4	40	9,640	$30	$424.2K
J0717	8	20	59,200	$1	$278.4K
J1602	6	40	23,560	$10	$264.5K
J3262	7	20	40,900	$1	$202.7K
J1745	26	50	3,250	$30	$107K
J0897	178	250	2,400	$20	$91.2K
99214	575	7,860	160	$80	$23.2K
96413	35	150	140	$90	$22.1K
99213	4,990	7,690	100	$60	$10.8K
90694	1,027	1,050	70	$80	$9.5K

Showing 1–10 of 44

Related Providers

Other providers that share a Tax Identification Number (TIN) with David Chetrit, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Christopher Michaelis	SC	Emergency Medicine Physician	$3.3M	$0
David Lazar	SC	Rheumatology Physician	$2.7M	$0
Charles Degenhardt	GA	Rheumatology Physician	$2.4M	$0
Rabih Nayfe	SC	Rheumatology Physician	$2M	$0
Gerald Larochelle	SC	Rheumatology Physician	$1.9M	$0
Donald Eagerton	SC	Endocrinology, Diabetes & Metabolism Physician	$734.8K	$0
Douglas Conaway	SC	Rheumatology Physician	$678.8K	$0
Chad Huberty	SC	Family Medicine Physician	$510.3K	$0
Lisa Mount	SC	Internal Medicine Physician	$444K	$0
Neil Trask	SC	Cardiovascular Disease Physician	$368.8K	$0

Nearby Providers

Other providers in the same ZIP code as David Chetrit, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Acs Primary Care Physicians - Southeast PC	SC	Emergency Medicine Physician	$0	$81.7M
Grand Strand Pediatrics & Adolescent Medicine, P.A.	SC	Pediatric Adolescent Medicine Physician	$0	$28M
Grand Strand Regional Medical Center LLC	SC	General Acute Care Hospital	$0	$27.4M
Carolina Regional Surgery Center. Ltd	SC	Ambulatory Surgical Clinic/Center	$3M	$1.7M
Coastal Carolina Primary Care, LLC	SC	Endocrinology, Diabetes & Metabolism Physician	$0	$4M
Brandon Coakley	SC	MOHS-Micrographic Surgery Physician	$3.5M	$0
Parkway Surgery Center	SC	Ambulatory Surgical Clinic/Center	$3.5M	$0
Jordan Henderson	SC	Hematology & Oncology Physician	$3.1M	$0
Dejuania Brown-rawls	SC	Hematology & Oncology Physician	$2.8M	$0
Stephen Hammond	SC	Dermatopathology Physician	$2.3M	$0

David Chetrit — Billing Profile & Reimbursement Data

Sign up for David Chetrit — Billing Profile & Reimbursement Data policy alerts

David Chetrit — Billing Profile & Reimbursement Data

Sign up for David Chetrit — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References